AI-powered search
AI-powered search

2023 Fall Clinical Virtual Grand Rounds

2023 Virtual Grand Rounds Session 9: June 14, 2023 - Topical Non-Steroidal Management of Atopic Dermatitis and Psoriasis: Clinical Insights for Dermatology Providers


To learn the right answer to the following question, click "Start Activity"

Tapinarof 1% and roflumilast 0.15% are currently undergoing clinical trials for atopic dermatitis. What were the endpoints that we found in the studies?
A) In INTEGUMENT-1 (roflumilast), 65% of patients achieved EASI 75 at the 2-week mark
B) In ADORING 1 (tapinarof), less than half the patients achieved an EASI 75 and a meaningful reduction in itch at the 8-week mark
C) In ADORING 1 (tapinarof), over half the patients achieved an EASI 75 and a meaningful reduction in itch at the 4 week mark
D) In INTEGUMENT-1 (roflumilast), 30% of patients achieved EASI 75 at the 2-week mark


This activity is supported by educational grants from Arcutis, Dermavant, and Incyte.


In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

June 15, 2023

Expiration Date:

June 15, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Identify challenges associated with the use of topical corticosteroids in patients with atopic dermatitis (AD) and psoriasis

  • Review nonsteroid topical agents for the treatment of AD and psoriasis

  • Discuss clinical considerations for prescribing topical therapies to patients with AD and psoriasis

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
George Han, MD, PhD

Chief of Teledermatology 
System Medical Director for Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Mona Shahriari, MD

Dermatologist, Yale University School of Medicine
Central CT Dermatology
Cromwell, CT

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

George K. Han, MD, PhD

Grant/Research Support: Celgene, Janssen, Lilly, MC2, Pfizer, UCB, Boehringer Ingelheim, Bond Avillion, Athenex, Amgen

Consultant: Janssen, Lilly, Abbvie, Sanofi Genzyme Regeneron, UCN, Boehringer Ingelheim, LEO, Ortho, Amgen, BMS

Speakers’ Bureau or Honoraria: Pfizer, Abbvie, Sanofi Genzyme Regeneron, SUN, Ortho

Mona Shahriari, MD

Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union

Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB

Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved